VGA039

The 'fully human' IgG4 antibody targets Protein S to balance blood clotting, offering a universal haemostatic therapy for bleeding disorders. It's the first subcutaneous therapy for all VWD types, with a convenient dosing regimen. Phase I trial VIVID 1 showed favorable safety. Star Therapeutics, backed by life sciences investors, aims to accelerate VGA039's development for VWD treatment.

VGA039, an investigational monoclonal antibody by Star Therapeutics, received FDA Fast Track designation for treating von Willebrand disease (VWD). It targets Protein S to restore blood clotting balance, offering a convenient, subcutaneous therapy for all VWD types, potentially reducing treatment burden.

The FDA granted Fast Track Designation to Star Therapeutics’ VGA039, a monoclonal antibody for von Willebrand disease (VWD), marking the first such designation for VWD. VGA039, a subcutaneous therapy, showed promising Phase I results, including high bioavailability and safety. It aims to reduce the treatment burden for VWD patients, affecting up to 1% of the population, with women more likely to experience symptoms.

VGA039, a novel monoclonal antibody therapy by Star Therapeutics, received FDA Fast Track designation for treating von Willebrand disease (VWD). It targets Protein S to restore blood clotting balance, offering a convenient, subcutaneous dosing regimen. This marks a significant advancement in VWD treatment, potentially reducing patient burden.

Star Therapeutics to present at the 43rd J.P. Morgan Healthcare Conference on January 14, 2025. CEO Adam Rosenthal will discuss VGA039, a novel therapy for von Willebrand disease and other bleeding disorders, aiming to reduce treatment burden.

Star Therapeutics announced interim clinical trial data for VGA039, a monoclonal antibody therapy for von Willebrand disease (VWD), showing 75% to 88% reductions in annualized bleed rates in three patients. VGA039, administered subcutaneously, offers a potential breakthrough by sustaining multi-week therapeutic concentrations, contrasting with current treatments requiring multiple intravenous infusions.

Star Therapeutics presented interim data from the VIVID 2 study at ASH 2024, showing VGA039, a subcutaneous monoclonal antibody, significantly reduced bleeding in Von Willebrand Disease (VWD) patients. VGA039 offers a convenient dosing regimen, potentially transforming VWD care by reducing treatment burden. Real-world data highlighted the high disease and treatment burden among VWD patients, underscoring the need for innovative therapies.

Star Therapeutics revealed Phase 1 trial results for VGA039, a potential universal hemostatic treatment for bleeding disorders, at the 32nd ISTH Congress. VGA039 showed high subcutaneous bioavailability and safety, aiming to ease treatment for von Willebrand disease patients.

VGA039 clinical data presented at ISTH 2024 shows a favorable safety profile and nearly 100% subcutaneous bioavailability in healthy volunteers, supporting a convenient dosing regimen for von Willebrand disease (VWD) treatment. The VIVID clinical program progresses with Phase 1 results indicating potential as a universal hemostatic therapy.